RE:RE:Is This Sector Becoming Saturated?RX is a very small company, only $100 mill mkt cap. Merus is over $300 mill, GUD $600 and Valeant way larger. As stated by RX, this allows the company to focus more on smaller products that the other companies may not feel are suitable because the Canadian market is too small. IMHO, this is a definite competitive advantage for RX. Seems like they are building up cash also, so they seem quite conservatively operated and able to potentially capitalize on any funding downturn within the Canadian drug industry.